Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Withdrawn 2Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

NET 3Endocrine 3Gastrointestinal 2

Conditions

Neuroendocrine Tumors 3Serotonin Syndrome 1Diarrhea 1Carcinoid Tumor 1

Interventions

lutetium Lu 177 dotatate 18Everolimus 13Temozolomide 12Nivolumab 10pembrolizumab 9cabozantinib 8Capecitabine 8Sunitinib 7lenvatinib 5Magnetic Resonance Spectroscopy 5Etoposide 5lanreotide 4gallium Ga 68 dotatate 4Specimen Handling 4Ipilimumab 4Cisplatin 4Carboplatin 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4telotristat ethyl 3surufatinib 3pazopanib 3avelumab 3Octreotide 3Injections 3Fluorodeoxyglucose F18 3Cyclophosphamide 3Bevacizumab 3sintilimab 2fosbretabulin 2fludarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × telotristat ethyl × NET × Clear all
NCT04543955 2023-06-27

Telotristat With Lutathera in Neuroendocrine Tumors

University of Kentucky

Phase 2 Terminated
1 enrolled 4 charts
EndocrineNET

Neuroendocrine Tumors

NCT04713202 2023-02-10

NET-PACS

Big Ten Cancer Research Consortium

Phase 2 Withdrawn
EndocrineNET

Diarrhea, Neuroendocrine Tumors, Serotonin Syndrome

NCT04672876 2021-12-17

Telotristat Ethyl for Reducing Intraoperative Carcinoid Crisis in Patients With Neuroendocrine Tumors

University of Chicago

Phase 2 Withdrawn
EndocrineNET

Carcinoid Tumor, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡